top of page

Search Results

Search this site

658 results found with an empty search

  • Renalytix and Quest Diagnostics partner to expand kidneyintelX.dkd testing across the US

    Renalytix has signed a multi-year agreement with Quest Diagnostics to expand US access to its kidneyintelX.dkd blood test for patients with type 2 diabetes and chronic kidney disease. The collaboration is designed to make kidneyintelX.dkd accessible through Quest's national diagnostics network, broadening physician access to a test that assesses risk of progressive kidney-function decline. kidneyintelX.dkd is FDA-authorised and Medicare-reimbursed, supporting its use in identifying higher-risk patients who may benefit from earlier intervention and more intensive disease management. Field Content Alert Type Industry Update Companies Renalytix; Quest Diagnostics Agreement Type Multi-year diagnostics collaboration Product kidneyintelX.dkd Therapy Area Chronic kidney disease; type 2 diabetes Technology or Modality Blood-based prognostic diagnostic test Geography United States What Happened Renalytix signed a multi-year agreement with Quest Diagnostics to expand access to kidneyintelX.dkd through Quest's US diagnostics network. Why It Matters Quest's national reach could materially increase physician and patient access to kidneyintelX.dkd. Supporting Context The test is FDA-authorised and Medicare-reimbursed for assessing risk of progressive kidney-function decline in adults with type 2 diabetes and early-stage chronic kidney disease. Potential Impact Broader access could support earlier risk stratification and more targeted intervention for patients at increased risk of kidney disease progression. Key Takeaway Renalytix is partnering with Quest Diagnostics to expand US access to kidneyintelX.dkd. What to Watch Commercial rollout through Quest and subsequent adoption by physicians and health systems. Primary Source Renalytix Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Novacyt and Illumina sign five-year collaboration framework

    Novacyt and Illumina have entered into a five-year master collaboration agreement to explore molecular-diagnostics product development and commercial opportunities. The agreement creates a framework for the companies to combine Novacyt's molecular-diagnostics capabilities with Illumina's sequencing and array technologies across potential future projects. The collaboration is an enabling framework rather than a commitment to a single product programme, with individual projects expected to require separate agreements. Field Content Alert Type Industry Update Companies Novacyt; Illumina Agreement Type Master collaboration agreement Agreement Term Five years Sector Molecular diagnostics; genomics Technology or Modality Molecular diagnostics, DNA sequencing and array technologies Geography Global What Happened Novacyt and Illumina entered into a five-year master collaboration agreement to explore future product-development and commercial opportunities. Why It Matters The framework links Novacyt's molecular-diagnostics capabilities with Illumina's sequencing and array technologies. Supporting Context Specific projects arising from the framework are expected to be governed by separate agreements. Potential Impact Successful projects could broaden Novacyt's diagnostic-development capabilities and create new applications using Illumina technologies. Key Takeaway Novacyt and Illumina have established a five-year framework for potential molecular-diagnostics collaboration. What to Watch Announcement of specific projects or commercial programmes under the collaboration. Primary Source Novacyt Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • BeOne Medicines reaches US government agreement on cancer medicine access and pricing

    BeOne Medicines has reached a voluntary agreement with the US government covering cancer medicine access, future pricing and continued investment in US pharmaceutical manufacturing. BeOne has joined the US government's GENEROUS pricing model and committed to internationally aligned pricing for future FDA-approved medicines. The company has also secured a Section 232 pharmaceutical tariff exemption linked to its US manufacturing investment, connecting medicine pricing, market access and domestic production strategy. Field Content Alert Type Industry Update Company BeOne Medicines Agreement Type US government pricing and access agreement Sector Oncology; pharmaceutical pricing; manufacturing Programme GENEROUS pricing model Geography United States What Happened BeOne Medicines announced a voluntary agreement with the US government covering medicine access, future pharmaceutical pricing and continued investment in domestic manufacturing. Pricing Commitment BeOne joined the GENEROUS pricing model and committed to internationally aligned pricing for future FDA-approved medicines. Tariff Treatment The company secured a Section 232 pharmaceutical tariff exemption linked to its US manufacturing investment. Why It Matters The agreement connects pharmaceutical pricing, patient access and domestic manufacturing policy in a way that could influence commercial strategy for oncology medicines in the United States. Potential Impact The commitments could affect future launch pricing, Medicaid access and BeOne's US manufacturing economics. Key Takeaway BeOne has combined US pricing commitments with domestic manufacturing investment and a pharmaceutical tariff exemption. What to Watch Implementation of the pricing commitments and further expansion of BeOne's US manufacturing footprint. Primary Source BeOne Medicines Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • ArsenalBio cuts 99 jobs as it pivots to in vivo CAR-T development

    ArsenalBio is cutting 99 jobs as it restructures the company around a strategic shift towards in vivo CAR-T development. The reduction represents the majority of ArsenalBio's workforce and concentrates resources on a smaller core team focused on its new in vivo cell-therapy strategy. The restructuring marks a significant change from the company's previous development model and reflects growing industry interest in CAR-T therapies that can potentially be generated directly inside patients. Field Content Alert Type Industry Update Company ArsenalBio Update Type Restructuring and R&D strategy shift Jobs Affected 99 employees Strategic Focus In vivo CAR-T development Therapy Area Oncology; cell therapy Technology or Modality CAR-T cell therapy Geography United States What Happened ArsenalBio is eliminating 99 positions as part of a restructuring that shifts the company's development focus towards in vivo CAR-T therapies. Why It Matters The workforce reduction and strategic pivot represent a material change in ArsenalBio's R&D model and technology priorities. Strategic Rationale A smaller core team will focus resources on development of the company's in vivo CAR-T strategy. Potential Impact The restructuring could substantially alter ArsenalBio's pipeline, workforce requirements and future financing needs. Key Takeaway ArsenalBio is cutting most of its workforce and repositioning the company around in vivo CAR-T development. What to Watch Details of the in vivo CAR-T pipeline and the future of ArsenalBio's existing programmes. Primary Source BioSpace Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Roche signs $1.53bn global licensing deal for Simcere's B-cell antibody SIM0660

    The agreement gives Roche exclusive global rights to develop, manufacture and commercialise Simcere Zaiming's investigational trispecific antibody SIM0660 outside Greater China. Roche has entered into a global licensing agreement for SIM0660, an investigational CD79a/CD19/CD3 trispecific antibody being developed by Simcere Zaiming for B-cell malignancies and autoimmune diseases. Simcere is eligible to receive up to $1.53 billion under the agreement, including a $75 million upfront payment, development and commercial milestone payments and tiered royalties on future sales. Field Content Alert Type Deal Companies Roche; Simcere Zaiming Deal Type Exclusive licensing agreement Asset or Company SIM0660 Therapy Area(s) B-cell malignancies; autoimmune diseases Technology or Modality CD79a/CD19/CD3 trispecific antibody Deal Value Up to $1.53 billion, including $75 million upfront plus potential development and commercial milestone payments; Simcere is also eligible for tiered royalties on future sales Development Stage Clinical-stage Geography Global rights outside Greater China What Happened Roche secured exclusive rights outside Greater China to develop, manufacture and commercialise SIM0660, Simcere Zaiming's investigational CD79a/CD19/CD3 trispecific antibody. Why It Matters The agreement adds a differentiated B-cell-targeting programme to Roche's pipeline with potential applications across both haematological malignancies and autoimmune diseases. Supporting Context SIM0660 is designed to engage CD3-positive T cells while targeting CD79a and CD19 on B cells, providing a dual B-cell-targeting approach. Strategic Rationale The licence gives Roche access to a potentially differentiated B-cell-directed therapy while allowing Simcere to retain rights in Greater China. Potential Impact Successful development could broaden therapeutic options for diseases driven by pathogenic or malignant B cells. Key Takeaway Roche is committing up to $1.53 billion to secure global rights outside Greater China to Simcere's trispecific B-cell antibody SIM0660. What to Watch Further clinical development of SIM0660 and progress across its oncology and autoimmune indications. Primary Source Simcere Pharmaceutical Group Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Cipla licenses HER2 bispecific ADC TQB2102 from Sino Biopharmaceutical

    The agreement gives Cipla exclusive rights to develop and commercialise the investigational HER2-targeted bispecific antibody-drug conjugate TQB2102 across India, South Africa and five additional emerging markets. Cipla has entered into an exclusive licensing agreement with Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical Group for TQB2102, a bispecific antibody-drug conjugate targeting HER2. The deal expands Cipla's oncology pipeline with a late-stage asset being investigated across multiple HER2-expressing cancers, including breast and gastric cancers. Field Content Alert Type Deal Companies Cipla; Sino Biopharmaceutical; Chia Tai Tianqing Pharmaceutical Group Deal Type Exclusive licensing agreement Asset or Company TQB2102 Therapy Area(s) Oncology; HER2-expressing cancers Technology or Modality HER2-targeted bispecific antibody-drug conjugate Deal Value Financial terms were not disclosed Development Stage Late-stage clinical development Geography India, South Africa and five additional emerging markets What Happened Cipla entered into an exclusive licensing agreement with Chia Tai Tianqing Pharmaceutical Group, part of Sino Biopharmaceutical, covering the development and commercialisation of TQB2102 in India, South Africa and five additional emerging markets. Why It Matters The agreement gives Cipla access to a differentiated late-stage HER2-targeted oncology asset and strengthens its speciality oncology pipeline across important emerging markets. Supporting Context TQB2102 is a bispecific antibody-drug conjugate being evaluated for the treatment of multiple HER2-expressing cancers. Strategic Rationale The licence supports Cipla's strategy of expanding access to innovative oncology medicines while adding an advanced targeted therapy to its portfolio. Potential Impact If successfully developed and approved, TQB2102 could expand treatment options for patients with HER2-expressing tumours across Cipla's licensed territories. Key Takeaway Cipla has secured exclusive rights to a late-stage HER2 bispecific ADC across seven emerging markets, strengthening its targeted oncology portfolio. What to Watch Clinical development of TQB2102, subsequent regulatory filings and the programme's progression towards commercialisation in the licensed territories. Primary Source Cipla Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • European Commission approves Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer

    The European Commission has approved Enhertu plus pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. The approval introduces a new first-line HER2-directed regimen in the European Union based on results from the Phase III DESTINY-Breast09 trial. Enhertu plus pertuzumab significantly reduced the risk of disease progression or death compared with the established taxane, trastuzumab and pertuzumab regimen, providing a new treatment option for eligible patients. Field Content Alert Type Approval Drug Name Trastuzumab deruxtecan plus pertuzumab Brand Name Enhertu plus Perjeta Company AstraZeneca; Daiichi Sankyo; Roche Regulatory Authority European Commission Approval Type Marketing authorisation / indication approval Indication First-line treatment of adults with unresectable or metastatic HER2-positive breast cancer Therapy Area(s) Oncology; breast cancer Geography European Union What Happened The European Commission approved Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. Why It Matters The approval establishes a new first-line HER2-directed treatment option in the EU and represents the first major change to the treatment approach in this setting in more than a decade. Supporting Context The approval was supported by results from the Phase III DESTINY-Breast09 trial comparing Enhertu plus pertuzumab with the established taxane, trastuzumab and pertuzumab regimen. Key Takeaway European approval of Enhertu plus pertuzumab introduces a new first-line standard option for eligible adults with unresectable or metastatic HER2-positive breast cancer. What to Watch Adoption of the combination across European markets and its impact on the sequencing of HER2-directed therapies in metastatic breast cancer. Primary Source AstraZeneca Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Ascendis and BioMarin agree global Yuviwel patent settlement and licence

    The binding term sheet resolves litigation between Ascendis Pharma and BioMarin while granting Ascendis a worldwide licence covering YUVIWEL and other navepegritide-related products. BioMarin has agreed to grant Ascendis a non-exclusive, worldwide, royalty-bearing licence allowing it to continue researching, developing, manufacturing and commercialising navepegritide-related products without restriction. Ascendis will pay BioMarin royalties equal to 20% of US net sales and 18% of net sales in the European Union, South Korea and Brazil from first commercial sale through 20 May 2030, while the companies will dismiss their respective proceedings. Field Content Alert Type Industry Update Companies Ascendis Pharma; BioMarin Pharmaceutical Agreement Type Global settlement and licence agreement Product YUVIWEL (navepegritide) Therapy Area Achondroplasia and skeletal dysplasias Technology or Modality C-type natriuretic peptide prodrug Geography Global What Happened On 31 August 2026, Ascendis Pharma and BioMarin entered into a binding term sheet setting out the terms of a global settlement and licence agreement related to YUVIWEL and other navepegritide-related products. The agreement is intended to resolve litigation and disputes between the companies. Licence Terms BioMarin will grant Ascendis a non-exclusive, worldwide, royalty-bearing licence allowing Ascendis to continue researching, developing, manufacturing and commercialising navepegritide-related products without restriction. Royalty Terms Ascendis will pay BioMarin royalties equal to 20% of US net sales and 18% of net sales in the European Union, South Korea and Brazil from first commercial sale in each territory through 20 May 2030. Why It Matters The settlement removes a material intellectual-property dispute surrounding Ascendis' navepegritide franchise and provides a defined framework for continued global development and commercialisation. Supporting Context BioMarin has also agreed to waive certain regulatory rights and exclusivities, dismiss proceedings and provide a covenant not to sue relating to the covered intellectual property. Potential Impact Resolution of the dispute could reduce legal uncertainty around YUVIWEL and allow Ascendis to focus on commercial expansion and further development of navepegritide-related products. Key Takeaway Ascendis has secured a worldwide licence and global settlement with BioMarin covering YUVIWEL and navepegritide-related products in exchange for defined royalty payments through May 2030. What to Watch Execution of the definitive settlement agreement and the commercial trajectory of YUVIWEL across the covered markets. Primary Source Ascendis Pharma Relevant Date 31 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Lilly agrees acquisition of Merida Biosciences in deal worth up to $2.875bn

    Lilly’s planned acquisition of Merida Biosciences adds an antibody-engineering platform designed to selectively remove disease-causing antibodies while preserving normal immune function. Eli Lilly has entered into a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and contingent milestone payments. The transaction strengthens Lilly’s immunology portfolio and brings in Merida’s lead programme MER511, which has shown early Phase 1 reductions in pathogenic thyroid-stimulating antibodies. Field Content Alert Type Deal Companies Eli Lilly and Company; Merida Biosciences Deal Type Acquisition Asset or Company Merida Biosciences Therapy Area(s) Autoimmune and allergic diseases Technology or Modality Antibody-engineering platform designed to selectively degrade pathogenic autoantibodies Lead Programme MER511 Deal Value Up to $2.875 billion in cash, including an upfront payment and contingent milestone payments Geography United States What Happened On 31 August 2026, Eli Lilly and Merida Biosciences announced a definitive agreement under which Lilly will acquire Merida for up to $2.875 billion in cash. Why It Matters The acquisition expands Lilly's immunology capabilities with a platform designed to target and remove disease-causing antibodies while preserving normal immune function. Supporting Evidence Initial Phase 1 data for MER511 showed robust reductions in pathogenic thyroid-stimulating antibodies with a favourable initial safety profile. Supporting Context Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies implicated in a range of immune-mediated diseases. Strategic Rationale Lilly gains a precision immunology platform and pipeline that could complement its existing presence in autoimmune and allergic diseases. Potential Impact If successfully developed, Merida's programmes could provide new therapeutic approaches for immune-mediated conditions driven by pathogenic antibodies. Key Takeaway Lilly is investing up to $2.875 billion to acquire Merida and add a differentiated antibody-degradation platform to its immunology portfolio. What to Watch Regulatory approvals, expected transaction completion in the fourth quarter of 2026 and further clinical development of MER511. Primary Source Eli Lilly and Company Relevant Date 31 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Besremi for adults with essential thrombocythemia

    The FDA has approved Besremi for adults with essential thrombocythemia, extending ropeginterferon alfa-2b-njft into a second myeloproliferative neoplasm indication in the United States. Besremi is administered by subcutaneous injection and was evaluated in the randomised SURPASS ET study against anagrelide in adults with essential thrombocythemia. The approval provides a new treatment option for a rare blood disorder characterised by excessive platelet production and associated risks of thrombosis and bleeding. Field Content Alert Type Approval Regulatory Authority U.S. Food and Drug Administration (FDA) Product Besremi (ropeginterferon alfa-2b-njft) Company PharmaEssentia Indication Treatment of adults with essential thrombocythemia Therapy Area Hematology / myeloproliferative neoplasms Technology or Modality Long-acting monopegylated interferon alfa Geography United States What Happened The FDA approved Besremi (ropeginterferon alfa-2b-njft) injection for the treatment of adults with essential thrombocythemia. Dosing The recommended starting dosage is 250 mcg by subcutaneous injection, increasing to 350 mcg at two weeks and a maintenance dosage of 500 mcg at four weeks, with maintenance dosing every two weeks unless modification is required for tolerability. Supporting Evidence The effectiveness of Besremi was evaluated in SURPASS ET, an open-label, multicentre, randomised study comparing Besremi with anagrelide in adults with essential thrombocythemia. Why It Matters Essential thrombocythemia can increase the risk of blood clots and bleeding because of excessive platelet production, and the approval provides another treatment option for affected adults. Supporting Context Besremi was already approved in the United States for polycythemia vera, another myeloproliferative neoplasm. Potential Impact The expanded indication could broaden use of ropeginterferon alfa-2b-njft across myeloproliferative neoplasms and provide physicians with an additional disease-directed treatment option. Key Takeaway FDA approval extends Besremi into essential thrombocythemia, giving adults with the rare blood disorder a newly authorised interferon-based treatment option. What to Watch Clinical adoption of Besremi in essential thrombocythemia and its positioning relative to established cytoreductive therapies. Primary Source U.S. Food and Drug Administration Relevant Date 31 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Mimrylo for adults with polycythemia vera

    Mimrylo is the first FDA-approved polycythemia vera treatment designed to mimic hepcidin, targeting the iron availability that drives excessive red blood cell production. The FDA approved Mimrylo (rusfertide) for treatment of erythrocytosis in adults with polycythemia vera whose disease has not been adequately controlled with existing therapies. By limiting the iron available for red blood cell production, the first-in-class therapy offers a new mechanism for controlling hematocrit and reducing the burden associated with excessive erythrocyte production. Field Content Alert Type Approval Regulatory Authority U.S. Food and Drug Administration (FDA) Product Mimrylo (rusfertide) Indication Treatment of erythrocytosis in adults with polycythemia vera Therapy Area Hematology / myeloproliferative neoplasms Technology or Modality Hepcidin mimetic Geography United States What Happened On 28 August 2026, the FDA approved Mimrylo (rusfertide) for adults with polycythemia vera, a rare blood disorder characterised by excessive red blood cell production. Mechanism Rusfertide mimics hepcidin, a hormone that regulates iron availability. By limiting the iron available for production of new red blood cells, the therapy helps reduce erythrocytosis. Why It Matters Mimrylo is the first approved treatment for polycythemia vera that mimics hepcidin, introducing a new mechanism of action for patients whose disease is not adequately controlled with existing therapies. Supporting Context Excess red blood cells can thicken the blood and increase the risk of complications including blood clots, stroke and heart attack. Potential Impact The approval provides clinicians with a new disease-control strategy that directly targets the biology supporting excessive red blood cell production. Key Takeaway FDA approval establishes Mimrylo as the first-in-class hepcidin-mimetic treatment for erythrocytosis in adults with polycythemia vera. What to Watch Uptake in patients requiring better hematocrit control and the therapy's positioning alongside existing cytoreductive and phlebotomy-based management strategies. Primary Source U.S. Food and Drug Administration Relevant Date 28 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • European Commission approves Daybu as first treatment for Rett syndrome in the EU

    The authorisation gives patients aged five years and older the first treatment specifically approved for Rett syndrome across the European Union, with Acadia preparing for an initial German launch in the fourth quarter of 2026. The European Commission has granted marketing authorisation to Daybu (trofinetide) for the treatment of neurobehavioural symptoms associated with Rett syndrome in patients aged five years and older, making it the first and only authorised treatment for the condition in the EU. The decision extends trofinetide’s regulatory reach beyond existing approvals in the US, Canada and Israel and follows a regulatory process in which Acadia Pharmaceuticals pursued re-examination after an earlier negative CHMP assessment. Field Content Alert Type Drug Approval Drug Name Daybu (trofinetide) Indication Treatment of neurobehavioural symptoms associated with Rett syndrome in patients aged five years and older. (BiotechDispatch) Therapy Area(s) Neurology; Rare disease; Neurodevelopmental disorders Geography European Union; Iceland; Liechtenstein; Norway What Happened On 25 August 2026, the European Commission granted marketing authorisation for Daybu (trofinetide) to treat neurobehavioural symptoms associated with Rett syndrome in patients aged five years and older. The authorisation applies across all 27 EU member states and extends to Iceland, Liechtenstein and Norway. Acadia Pharmaceuticals holds the exclusive worldwide licence to develop and commercialise trofinetide from Neuren Pharmaceuticals. Daybu becomes the first and only authorised treatment specifically for Rett syndrome in the EU. (BiotechDispatch) Why It Matters Until this authorisation, there was no treatment specifically approved for Rett syndrome in the EU. Daybu therefore introduces a disease-specific pharmacological treatment option for eligible European patients and extends access to a therapy already commercialised in other markets, including the US and Canada. (BiotechDispatch) Supporting Context The European approval follows an extended regulatory process. Acadia originally submitted the MAA in January 2025, but in February 2026 the CHMP communicated a negative trend vote, prompting plans for re-examination. The subsequent European Commission authorisation therefore represents a reversal of the programme's earlier regulatory trajectory. (Neuren Pharmaceuticals) Key Takeaway European approval makes Daybu the first authorised treatment specifically for Rett syndrome in the EU and expands trofinetide into another major commercial market. What to Watch Acadia expects to launch Daybu in Germany early in the fourth quarter of 2026. Under its licensing agreement, Neuren is due $35 million following the first commercial sale in Europe and is eligible for up to $170 million in European sales milestones plus tiered royalties ranging from the mid-teens to low twenties per cent. (BiotechDispatch) Primary Source Acadia Pharmaceuticals / Neuren Pharmaceuticals Relevant Date 25 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page